MARKET

JAGX

JAGX

Jaguar Health Inc
NASDAQ
7.77
-0.74
-8.70%
After Hours: 7.82 +0.05 +0.64% 19:33 05/12 EDT
OPEN
8.51
PREV CLOSE
8.51
HIGH
8.93
LOW
7.55
VOLUME
125.92K
TURNOVER
--
52 WEEK HIGH
502.35
52 WEEK LOW
4.020
MARKET CAP
5.24M
P/E (TTM)
-0.0595
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JAGX last week (0505-0509)?
Weekly Report · 18h ago
Jaguar Health Inc <JAGX.OQ> expected to post a loss of $18.00 a share - Earnings Preview
Reuters · 3d ago
Jaguar Health Registers 1.29M Shares Of Common Stock For Resale From Private Placement That Closed On March 31, 2025, Including Shares Issuable From Convertible Notes, Common Warrants, And Placement Agent Warrants
Benzinga · 4d ago
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News
Barchart · 5d ago
Jaguar Health provides overview of 2025 crofelemer-related catalysts
TipRanks · 5d ago
Weekly Report: what happened at JAGX last week (0428-0502)?
Weekly Report · 05/05 11:52
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 04/30 21:05
Jaguar Health Announces Initial Proof-Of-Concept Results Showing That Novel Liquid Formulation Of Crofelemer Reduced Required TPN And/Or Supplementary Intravenous Fluids In MVID And SBS-IF Patients
Benzinga · 04/30 12:29
More
About JAGX
More
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Recently
Symbol
Price
%Change

Webull offers Jaguar Health Inc stock information, including NASDAQ: JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.